Irbesartan + Hidroclorotiazida Aurovitas

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartan + Hidroclorotiazida Aurovitas, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for systemic use. The combination therapy reduces blood pressure by targeting vascular tone and fluid balance, and is indicated for the management of hypertension in adult patients.

GNH USA supplies Irbesartan + Hidroclorotiazida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier. The company serves hospitals, pharmacies, and clinics worldwide, providing reliable sourcing, regulatory support, and consistent product quality for cardiovascular therapy programs.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, acting on the renin‑angiotensin system and renal sodium handling.

Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. Essential hypertension: provides sustained blood‑pressure control when monotherapy is insufficient. Resistant hypertension: offers an additive effect through combined RAAS blockade and diuresis for patients needing additional pressure reduction.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or mild dehydration - Electrolyte disturbances such as low potassium - Mild gastrointestinal discomfort - Fatigue

Serious or Rare Side Effects: - Angioedema or severe swelling of face, lips, or throat - Acute kidney injury or significant rise in serum creatinine - Hyperkalemia or severe electrolyte imbalance - Marked hypotension leading to fainting - Severe allergic reactions such as rash or Stevens‑Johnson syndrome

Precautions should be observed before initiating therapy and during treatment.

Monitor blood pressure: adjust therapy if target levels are not achieved. Assess renal function: check serum creatinine and eGFR before and periodically while on treatment. Evaluate electrolyte balance: watch for sodium and potassium abnormalities. Avoid use in severe hepatic impairment: consider alternative therapy. Contraindicated in pregnancy: do not prescribe to pregnant women. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Irbesartan/Hydrochlorothiazide may interact with several medicines; review concomitant drugs.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood‑pressure lowering, may require dose adjustment. - Antidiabetic agents: blood‑glucose levels may change, monitor glycemic control.